Granted Patent B2

US 12,263,358 · App. 17/684,290 · Granted Apr 1, 2025

Inventor: John Mumm (Germantown, MD)

Assignee: DEKA BIOSCIENCES, INC.

C07K16/2896A61P35/00A61P37/06C07K14/5406C07K14/5428C07K14/55C07K16/10C07K16/1045C07K16/2803C07K16/2863C07K16/32C07K16/464A61K38/00A61K2039/505A61K2039/545C07K2317/53C07K2317/565C07K2317/622C07K2317/92C07K2319/30

Abstract

Claims (16)

1. A dual cytokine fusion protein of formula (I)

NH2-(IL-10)-(X 1 )—(Z n )—(X 2 )—(IL-10)-COOH  (Formula I);

wherein

“IL-10” is a monomer;

“X 1 ” is a VL or VH region from a first monoclonal antibody;

“X 2 ”′ is a VH or VL region from the first monoclonal antibody;

wherein when X 1 is a VL, X 2 is a VH or when X 1 is a VH, X 2 is a VL,

wherein the first monoclonal antibody is an anti-ebola antibody;

wherein the VL and VH from the anti-ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs that are engrafted with 3 light chain CDRs and 3 heavy chain CDRs from a second monoclonal antibody;

“Z” is a cytokine other than IL-10;

“n” is an integer of 1; and

wherein:

the IL-10 is SEQ ID No: 1, [14], the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-7.

2. A pharmaceutical composition comprising the dual cytokine fusion protein according to claim 1 , pharmaceutically acceptable buffers, and pharmaceutically acceptable excipients.

3. The fusion protein according to claim 1 , wherein the VH and VL regions comprise a framework region obtained from a human anti-Ebola antibody.

4. The fusion protein according to claim 3 , wherein the frame region from the anti-Ebola antibody is engrafted with the three VH CDRs and three VL CDRs from an anti-EGFR monoclonal antibody.

Assignments (3)

Continuity (4)

References Cited (133)